Cargando…

FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review

FLT3-mutated acute myeloid leukemia accounts for around 30% of acute myeloid leukemia (AML). The mutation carried a poor prognosis until the rise of tyrosine kinase inhibitors (TKIs). New potent and specific inhibitors have successfully altered the course of the disease, increasing the complete resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Loschi, Michael, Sammut, Rinzine, Chiche, Edmond, Cluzeau, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198781/
https://www.ncbi.nlm.nih.gov/pubmed/34070902
http://dx.doi.org/10.3390/ijms22115873